Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Fatigue Syndrome AND Fatigue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    156 result(s) found for: Chronic Fatigue Syndrome AND Fatigue. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2010-024069-30 Sponsor Protocol Number: CD-IA-MEDI-545-1067/D2800L00004 Start Date*: 2011-08-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) HU (Completed) ES (Completed) DE (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000134-37 Sponsor Protocol Number: 20010184 Start Date*: 2004-09-14
    Sponsor Name:Amgen Inc.
    Full Title: Trial to Reduce Cardiovascular Events with Aranesp Therapy
    Medical condition: Treatment of anaemia in subjects with chronic kidney disease (CKD) amd Type 2 diabetes mellitus (DM)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038444 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) SE (Completed) IT (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004290-97 Sponsor Protocol Number: ACCILTRA1 Start Date*: 2008-12-19
    Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
    Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle...
    Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005258-37 Sponsor Protocol Number: FCAT Start Date*: 2016-02-22
    Sponsor Name:LUMC
    Full Title: A randomized, double blind, placebo-controlled study on the effect of 3 months treatment with the analgesic tapentadol on conditioned pain modulation (CPM) and pain relief in patients with chronic ...
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10016631 Fibromyalgia syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004249-16 Sponsor Protocol Number: F02207GE204 Start Date*: 2005-02-02
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY
    Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000694-23 Sponsor Protocol Number: PCYC-1112-CA Start Date*: 2012-08-08
    Sponsor Name:Pharmacyclics LLC an Abbvie Company
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia...
    Medical condition: relapsed or refractory CLL/SLL
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10060671 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004403-14 Sponsor Protocol Number: BCX9930-203 Start Date*: 2021-11-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Noct...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) LT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000501-93 Sponsor Protocol Number: BCX9930-201 Start Date*: 2020-09-29
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000058-73 Sponsor Protocol Number: LIPS Start Date*: 2012-09-14
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Walton Centre NHS Foundation Trust
    Full Title: A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard tre...
    Medical condition: Complex Regional Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004867 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005140-16 Sponsor Protocol Number: APL2-202 Start Date*: 2018-07-18
    Sponsor Name:Apellis Pharmaceuticals
    Full Title: A Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001518-25 Sponsor Protocol Number: P-Monofer-IDA-02 Start Date*: 2014-11-21
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) against Placebo in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unrespon...
    Medical condition: Subjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anae...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010623-64 Sponsor Protocol Number: RPV-0802 Start Date*: 2009-04-02
    Sponsor Name:Renapharma AB
    Full Title: A clinical open, randomised study of oral iron (Duroferon®) vs. intravenous iron (Ferinject®) for iron substitution in blood donors.
    Medical condition: Iron deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022972 Iron deficiency anaemia LLT
    9.1 10022975 Iron deficiency anemia secondary to blood loss (chronic) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002761-33 Sponsor Protocol Number: R3918-PNH-2022 Start Date*: 2022-05-02
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGL...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003137-19 Sponsor Protocol Number: M-2022-398 Start Date*: 2023-05-30
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: An open-label phase I/IIa, multicenter, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE
    Medical condition: Adult patients with refractory active systemic lupus erythematosus (SLE) with organ involvement
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005776-35 Sponsor Protocol Number: 230LE304 Start Date*: 2021-12-24
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Ba...
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005558-63 Sponsor Protocol Number: V70P3 Start Date*: 2006-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nona...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002714-23 Sponsor Protocol Number: LLC1114 Start Date*: 2015-01-07
    Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL).
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10024340 Leukemia lymphocytic chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005661-14 Sponsor Protocol Number: CVAY736A2301 Start Date*: 2022-06-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1)
    Medical condition: Active Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) LT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 20:16:55 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA